About B2S Life Sciences
We provide superior custom reagent products and services that are tailored to our clients’ needs and manage these products and services for clients throughout the drug development process with pre-analytical and post-analytical services.
Our combination of expertise, products, and services thereby uniquely qualifies us to better the development process for biotherapeutic drugs, CROs, pharma, biotech and diagnostics.
Meet Our Team
Executive Team
Technical Team
Derrick Johnson, PhD
Director of Assay Development
Sanofar J. Abdeen PhD
Associate Director – R&D Custom Reagents
Swarna Ramaswamy PhD
Lead Research Scientist
Sherri Rinker, PhD
Associate Director of Regulated Bioanalysis
Rick Delhaye
Principal Investigator (Team Lead)
Nathan McOwen
Scientist III
Adam Kinne
Senior Scientist, Custom Reagents
Vish Chandrahas
Sr. Scientist II
Elizabeth Rempala
Manager of Quality Operations
Hannah Gill
Operations Supervisor
Jamie Colwell
Logistics Sample Inventory Supervisor
Business Team
Julie Williams
Project Coordinator
Charla Smith
Business Development Coordinator
Lori Huddleston
Business Operations Manager
Amy Fisher SHRM-CP
Human Resources Manager
Ronald R. Bowsher PH.D.
Partner & Chief Scientific Officer
Dr. Bowsher’s career in the pharmaceutical/biotechnology and CRO industries has spanned 41⁄2 decade, including 3 decades at the Lilly Research Labs and nearly 2 decades as a consultant and an advisor in the CRO industry. He is a recognized thought-leader in the areas of bioanalytical methods development for regulatory-compliant bioanalysis, ADME and immunogenicity assessments of biotherapeutics. He received his M.S. and Ph.D. degrees in Biochemistry & Molecular Biology at the Indiana University School of Medicine (Indianapolis, IN). Currently, he is Partner and CSO at B2S Life SciencesTM (www.B2SLifeSciences.com), a biotechnology drug development support laboratory in Franklin, IN specializing in the generation and life-cycle management of custom biological reagents, ligand binding assay development and ADME, and data analytics to support biotherapeutic drug development. In 2003, Dr. Bowsher retired from the Lilly Research Laboratories where he led research groups responsible for supporting regulated bioanalysis of biotherapeutics and conventional small molecule drugs by ligand binding assay methodology. His Lilly tenure included more than a decade of experience as the Lilly Clinical Radiation Safety Officer and as a member of the Lilly Corporate and IUMC Radiation Safety and Radionuclide Human Use committees. Since 1980, he has published > 250 research papers, monographs, and abstracts, has four patents, 75 invited lectures, been a consultant to > 100 global companies and has served on several scientific advisory boards. In 2000, he led creation of the Ligand Binding Focus Group within AAPS which culminated in a number of key white papers with emphasis on ligand binding assays for supporting PK of biotherapeutics, ADA testing and quantitative biomarker assessments. In 2004, Dr. Bowsher was elected as an AAPS Fellow. In 2008, he was given an AAPS Presidential citation for his efforts to establish educational training programs for supporting Biotech R&D. In 2011, Dr. Bowsher received the AAPS BIOTEC Section distinguished service award.
Aleks Davis BS, MBA
Partner & Chief Executive Officer
Aleks Davis has over twenty years of experience in biotechnology industry with a proven track record in multiple facets of drug development. As a project director in Tailored Therapeutics at Eli Lilly and Company, Aleks was responsible for the planning, implementation and financial tracking of projects supporting early stage biomarker hypothesis. Several of these projects were in the neuroscience field. As the global director at ICON PLC, Aleks developed policies and procedures, business development strategies, marketing and profit and loss accountability. There he directed operations spanning four continents. Now at B2S Life Sciences, Aleks is the CEO and works with over one hundred different clients by helping them navigate the important, yet, challenging aspects of bioanalysis in biotherapeutic development. His Chemistry degree is from Georgia Southern University and Executive MBA is from Kelley School of Business, Indiana University. In 2019, he was a member of the B2S Life Sciences team that was honored by the Small Business Administration as Indiana’s Exporter of the Year.
Who We Are
B2S Life Sciences is not a typical CRO. Rather, we are a Biotherapeutic Enablement Company. We advance biotherapeutic drug development by providing optimized critical reagents for improved analytical methods and outcomes for companies involved in the development of biotherapeutic drugs and diagnostics. Additionally, we provide support for biotherapeutic drug development from late phase discovery through BLA submission. Our major focus is on the design, generation, purification and life cycle management of custom critical reagents to support Regulated Bioanalysis and CMC assays of biotherapeutics. Our custom reagents are specifically designed and manufactured to be optimal for the intended analytical purpose. Moreover, we store our custom critical reagents in our proprietary LCM+ inventory system to maintain these products in a controlled manner to help ensure long term stability, consistency in performance and provide a well-documented chain-of-custody for regulatory compliance. When combined with our range of downstream services novel business model and services uniquely qualifies us to meet the drug development needs for pharma, biotech, CROs and diagnostics.
Our mission is to leverage our extensive expertise in bioanalytical methods, development and statistical analysis to:
- Help ensure technical success
- Create value
- Make a positive impact on discovery and development projects and regulatory submissions for our clients’ therapeutic products and devices.
Our Core Mission
B2S Life Science’s CORE MISSION is to design, generate, purify, characterize, and perform life cycle management of custom critical reagents, combined with complementary downstream activities, including:
- Assay development and qualification
- Non-GLP bioanalysis and CRO oversight for GLP bioanalysis
- Data analytics services, including PK/TK, immunogenicity cut point statistics, clinical immunogenicity, and support for IND/NDA/BLA submissions
B2S Life Sciences strives to maximize R&D quality and efficiency by enabling successful regulatory submissions of biotherapeutics.
B2S Life Sciences Offers:
- Pre-Analytical thru Post-Analytical services to extend the range of capabilities typically found at conventional bioanalytical CROs
- Provide services for unmet drug development needs
- Serve as a consultative advisory partner
- Support both large & small molecule therapeutic
Our History
Incorporated in 2002 as Bowsher Brunelle Smith LLC (d/b/a B2S Consulting), we were founded as an Indianapolis-based firm offering a range of consulting services to support research and development of biotherapeutics and conventional pharmaceuticals.
Leveraging decades of combined experience in drug development and applied statistics, Dr. Ronald Bowsher and his business partners offered cutting-edge and in-depth support for nonclinical and clinical drug development.
In January 2017, our core competencies were consolidated under the network of B2S Life Sciences, a service-driven biotherapeutic enablement company offering premier laboratory analysis and life cycle management of custom reagents.
Today, B2S Life Sciences serves pharma and biotechnology clients by offering a wide range of pre-analytical (generation of custom reagents) and post-analytical (data analytics and statistics, pharmacokinetic data analysis and clinical immunogenicity) services.
Contact us
We are here to help! Fill the contact form below to schedule a call with one of our scientists.
B2S Website Form - Contact Us
"*" indicates required fields